178 related articles for article (PubMed ID: 23807770)
1. Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs.
Cirstea D; Hideshima T; Santo L; Eda H; Mishima Y; Nemani N; Hu Y; Mimura N; Cottini F; Gorgun G; Ohguchi H; Suzuki R; Loferer H; Munshi NC; Anderson KC; Raje N
Leukemia; 2013 Dec; 27(12):2366-75. PubMed ID: 23807770
[TBL] [Abstract][Full Text] [Related]
2. AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition.
Santo L; Vallet S; Hideshima T; Cirstea D; Ikeda H; Pozzi S; Patel K; Okawa Y; Gorgun G; Perrone G; Calabrese E; Yule M; Squires M; Ladetto M; Boccadoro M; Richardson PG; Munshi NC; Anderson KC; Raje N
Oncogene; 2010 Apr; 29(16):2325-36. PubMed ID: 20101221
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways.
Saha MN; Jiang H; Chang H
Cancer Biol Ther; 2010 Sep; 10(6):567-78. PubMed ID: 20595817
[TBL] [Abstract][Full Text] [Related]
4. Functional p53 in cells contributes to the anticancer effect of the cyclin-dependent kinase inhibitor roscovitine.
Paprskárová M; Krystof V; Jorda R; Dzubák P; Hajdúch M; Wesierska-Gadek J; Strnad M
J Cell Biochem; 2009 Jun; 107(3):428-37. PubMed ID: 19308936
[TBL] [Abstract][Full Text] [Related]
5. Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription.
Manohar SM; Rathos MJ; Sonawane V; Rao SV; Joshi KS
Leuk Res; 2011 Jun; 35(6):821-30. PubMed ID: 21216463
[TBL] [Abstract][Full Text] [Related]
6. Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283.
Curry J; Angove H; Fazal L; Lyons J; Reule M; Thompson N; Wallis N
Cell Cycle; 2009 Jun; 8(12):1921-9. PubMed ID: 19440047
[TBL] [Abstract][Full Text] [Related]
7. Flavopiridol induces apoptosis in glioma cell lines independent of retinoblastoma and p53 tumor suppressor pathway alterations by a caspase-independent pathway.
Alonso M; Tamasdan C; Miller DC; Newcomb EW
Mol Cancer Ther; 2003 Feb; 2(2):139-50. PubMed ID: 12589031
[TBL] [Abstract][Full Text] [Related]
8. The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells.
Landau HJ; McNeely SC; Nair JS; Comenzo RL; Asai T; Friedman H; Jhanwar SC; Nimer SD; Schwartz GK
Mol Cancer Ther; 2012 Aug; 11(8):1781-8. PubMed ID: 22653969
[TBL] [Abstract][Full Text] [Related]
9. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.
Ma CX; Cai S; Li S; Ryan CE; Guo Z; Schaiff WT; Lin L; Hoog J; Goiffon RJ; Prat A; Aft RL; Ellis MJ; Piwnica-Worms H
J Clin Invest; 2012 Apr; 122(4):1541-52. PubMed ID: 22446188
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological inhibition of cyclin dependent kinases causes p53 dependent apoptosis in renal cell carcinoma.
Ishimaru T; Lau J; Jackson AL; Modiano JF; Weiss RH
J Urol; 2010 Nov; 184(5):2143-9. PubMed ID: 20850841
[TBL] [Abstract][Full Text] [Related]
11. Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines.
Shapiro GI; Koestner DA; Matranga CB; Rollins BJ
Clin Cancer Res; 1999 Oct; 5(10):2925-38. PubMed ID: 10537362
[TBL] [Abstract][Full Text] [Related]
12. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents.
Hirai H; Iwasawa Y; Okada M; Arai T; Nishibata T; Kobayashi M; Kimura T; Kaneko N; Ohtani J; Yamanaka K; Itadani H; Takahashi-Suzuki I; Fukasawa K; Oki H; Nambu T; Jiang J; Sakai T; Arakawa H; Sakamoto T; Sagara T; Yoshizumi T; Mizuarai S; Kotani H
Mol Cancer Ther; 2009 Nov; 8(11):2992-3000. PubMed ID: 19887545
[TBL] [Abstract][Full Text] [Related]
13. The cyclin-dependent kinase inhibitor 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole induces nongenotoxic, DNA replication-independent apoptosis of normal and leukemic cells, regardless of their p53 status.
Turinetto V; Porcedda P; Orlando L; De Marchi M; Amoroso A; Giachino C
BMC Cancer; 2009 Aug; 9():281. PubMed ID: 19674456
[TBL] [Abstract][Full Text] [Related]
14. Impact of roscovitine, a selective CDK inhibitor, on cancer cells: bi-functionality increases its therapeutic potential.
Wesierska-Gadek J; Borza A; Komina O; Maurer M
Acta Biochim Pol; 2009; 56(3):495-501. PubMed ID: 19724778
[TBL] [Abstract][Full Text] [Related]
15. Quantitative analysis of p53-targeted gene expression and visualization of p53 transcriptional activity following intratumoral administration of adenoviral p53 in vivo.
Ohtani S; Kagawa S; Tango Y; Umeoka T; Tokunaga N; Tsunemitsu Y; Roth JA; Taya Y; Tanaka N; Fujiwara T
Mol Cancer Ther; 2004 Jan; 3(1):93-100. PubMed ID: 14749479
[TBL] [Abstract][Full Text] [Related]
16. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.
Chen S; Dai Y; Pei XY; Myers J; Wang L; Kramer LB; Garnett M; Schwartz DM; Su F; Simmons GL; Richey JD; Larsen DG; Dent P; Orlowski RZ; Grant S
Cancer Res; 2012 Aug; 72(16):4225-37. PubMed ID: 22693249
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of cell growth by transforming growth factor beta 1 is associated with p53-independent induction of p21 in gastric carcinoma cells.
Akagi M; Yasui W; Akama Y; Yokozaki H; Tahara H; Haruma K; Kajiyama G; Tahara E
Jpn J Cancer Res; 1996 Apr; 87(4):377-84. PubMed ID: 8641969
[TBL] [Abstract][Full Text] [Related]
18. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma.
Raje N; Kumar S; Hideshima T; Roccaro A; Ishitsuka K; Yasui H; Shiraishi N; Chauhan D; Munshi NC; Green SR; Anderson KC
Blood; 2005 Aug; 106(3):1042-7. PubMed ID: 15827128
[TBL] [Abstract][Full Text] [Related]
19. Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications.
McMillin DW; Delmore J; Negri J; Buon L; Jacobs HM; Laubach J; Jakubikova J; Ooi M; Hayden P; Schlossman R; Munshi NC; Lengauer C; Richardson PG; Anderson KC; Mitsiades CS
Br J Haematol; 2011 Feb; 152(4):420-32. PubMed ID: 21223249
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.
DePinto W; Chu XJ; Yin X; Smith M; Packman K; Goelzer P; Lovey A; Chen Y; Qian H; Hamid R; Xiang Q; Tovar C; Blain R; Nevins T; Higgins B; Luistro L; Kolinsky K; Felix B; Hussain S; Heimbrook D
Mol Cancer Ther; 2006 Nov; 5(11):2644-58. PubMed ID: 17121911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]